New HIV drug shows promise in early trial to lower virus levels
NCT ID NCT07042945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new experimental drug, MK-4646, in people with HIV who have never taken HIV medications. The main goals are to see if the drug is safe and tolerable, and how much it can lower the amount of HIV in the blood. About 28 participants will receive the drug and be monitored closely. This is an early-stage trial to gather initial safety and effectiveness data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ARENSIA Exploratory Medicine ( Site 0001)
Bucharest, Bucharest, 021105, Romania
-
PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 0002)
Chisinau, 2025, Moldova
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
- Immune-Boosting cocktail aims to free HIV patients from daily medication